ed; erections; lib-01; sexual health

https://www.dicotpharma.com/en/press/press-releases/?slug=dicot-pharma-initiates-tablet-manufacturing-ahead-of-phase-2b-clinical-study Uppsala, Sweden, March 12, 2026. Dicot Pharma AB announces that the company has successfully completed the development of LIB-01 as a tablet and initiated...

This episode of BioBiz Buzz spotlights the rapidly growing global markets for erectile dysfunction (ED) and premature ejaculation (PE), conditions impacting over 500 million men worldwide. Your host Mike Ward interviews Elin Trampe, CEO of Dicot Pharma, who discusses the company’s innovative...

* “It’s amazing — it’s been a quarter of a century, and until recently, there really haven’t been any promising, competitive molecules that could match PDE5 inhibitors in terms of efficacy and tolerability.” * Unlike PDE5 inhibitors, which act locally to enhance and trap blood flow in the...